Hearing Gene Therapy and Biotech Shifts
Kilder
- STAT: STAT+: Skylark Bio kicks off new gene therapy trial for deafness
- Endpoints: Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
- BioPharma Dive: Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
- BioPharma Dive: Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs - BioPharma Dive
- Labiotech: Seven biotechs driving progress in Duchenne muscular dystrophy
- GEN: The State of Biotech 2026
- Fierce Biotech: Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60% - Fierce Biotech
- Endpoints: Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.